ArticleBMC medical ethics2026
Exploring experts' views on "Not Parent Expected" discoveries via direct-to-consumer DNA ancestry testing.
Article in BMC medical ethics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMillions of people have taken Direct-to-Consumer (DTC) DNA ancestry tests to learn more about their ethnic ancestry and family history. A small but growing body of research has noted that these DTC DNA ancestry tests raise challenging ethical, psychosocial, and resource-related issues that have not been adequately considered nor discussed. One key issue concerns a "Not Parent Expected" (NPE) discovery, in which a user suddenly and unexpectedly learns from these tests that an assumed parent (typically the father) is not a biological parent. Such news can negatively affect mental health, self-identity, and family relationships. Given the limited research on this topic, we aimed to explore experts' views on the ethical, psychosocial and support-related aspects of DTC DNA ancestry testing, particularly for individuals who receive NPE news.
methodsWe conducted a qualitative study. This involved semi-structured interviews with ten experts on DTC DNA ancestry testing, who had written about or actively researched these issues. The interviews were analysed using codebook thematic analysis.
resultsThe analysis resulted in three overlapping themes. The first concerned insufficient support for the NPE population, despite the emergence of some relevant resources. The supports discussed included formal resources, such as genetic counselling and therapy, as well as informal resources, including online peer support. Both formal and informal resources were seen as having advantages and disadvantages. The second theme concerned the need for better consideration of informed consent before taking these tests. Many experts reported that standard consent procedures do not fully prepare consumers for the possibility of making an unexpected discovery such as an NPE event. They suggested that this information could be communicated more effectively, including using creative measures before consent is obtained. The third theme related to the testing companies' role and responsibility in relation to support for individuals learning NPE news. A few experts suggested that these companies bear some moral responsibility, even in the absence of a legal obligation, to provide or direct individuals to supportive resources.
conclusionsTogether, these findings contribute to ongoing debates regarding DTC DNA ancestry testing by highlighting the need for greater support for those affected by NPE discoveries and clearer consideration of the responsibilities of testing companies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.